Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cunningham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cunningham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:179-182, 1996
© 1996 European Society for Medical Oncology

research-article

‘Tomudex’ (ZD1694)*: A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours,**

D. Cunningham, J. Zalcberg, I. Smith, M. Gore, R. Pazdur, H. Burris, III, N. J. Meropol, G. Kennealey, L. Seymour and the ‘Tomudex’ International Study Group

Background: Anti-metabolites such as methotrexate (MTX) and 5-fluorouracil (5-FU) have been used clinically for many years. Although their effects are partly due to thymidylate synthase (TS) inhibition, they also have non-specific, non TS effects on RNA and purine synthesis. Direct and specific TS inhibitors therefore presented an attractive research target Collaborative research between the Institute of Cancer Research and Zeneca Pharmaceuticals led to the design of specific folate based quinazoline TS inhibitors. ZD1694 ('Tomu-dex'), the first of these drugs reaching advanced clinical development, is currently completing phase III studies.

Design: Eight phase II trials were carried out using ‘Tomudex’, 3.0 mg/m2, given as a short 15-minute infusion 3-weekly.

Results: ‘Tomudex’ demonstrates activity in a range of tumour types, most notably advanced colorectal and breast cancer (objective response rate 26%) and has acceptable toxicity: the most common WHO grade 3 and 4 adverse events were self-limiting reversible increases in liver transaminases, transient leucopenia, diarrhoea, nausea and vomiting and tiredness or malaise. Mucositis/stomatitis, alopecia and skin toxicity were notable for their low incidence and mild intensity.

Conclusions: ‘Tomudex’ represents the successful culmination of a rational drug design programme, and shows promise as a new cytotoxic for the treatment of colorectal cancer. Further studies in other tumour types are planned.

colorectal cancer (advanced), thymidylate synthase inhibitor, ‘Tomudex’ (ZD1694)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
K. Fizazi, H. Doubre, T. Le Chevalier, A. Riviere, J. Viala, C. Daniel, L. Robert, P. Barthelemy, A. Fandi, and P. Ruffie
Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study
J. Clin. Oncol., January 15, 2003; 21(2): 349 - 354.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Papamichael
The Use of Thymidylate Synthase Inhibitors in the Treatment of Advanced Colorectal Cancer: Current Status
Oncologist, December 1, 1999; 4(6): 478 - 487.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. Cao, J. J. McGuire, and Y. M. Rustum
Antitumor Activity of ZD1694 (Tomudex) against Human Head and Neck Cancer in Nude Mouse Models: Role of Dosing Schedule and Plasma Thymidine
Clin. Cancer Res., July 1, 1999; 5(7): 1925 - 1934.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.